{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:24:49Z","timestamp":1769117089600,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.81770392, No.81770394, No.81700344, No.81800344, No.81800345"],"award-info":[{"award-number":["No.81770392, No.81770394, No.81700344, No.81800344, No.81800345"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Program Foundation of Guangdong","award":["No.2017A020215156"],"award-info":[{"award-number":["No.2017A020215156"]}]},{"DOI":"10.13039\/501100003785","name":"Medical Research Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["No.A2018107, No.A2018082"],"award-info":[{"award-number":["No.A2018107, No.A2018082"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10557-020-07011-y","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T10:02:44Z","timestamp":1592992964000},"page":"763-772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1007","volume":"34","author":[{"given":"Wengen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruicong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zexuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"7011_CR1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"key":"7011_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14503\/THIJ-14-4353","volume":"42","author":"W Zhu","year":"2015","unstructured":"Zhu W, Xiong Q, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Tex Heart Inst J. 2015;42:6\u201315.","journal-title":"Tex Heart Inst J"},{"key":"7011_CR3","doi-asserted-by":"publisher","first-page":"R665","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140:R665.","journal-title":"Circulation"},{"key":"7011_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/07853890.2016.1179390","volume":"48","author":"F Liu","year":"2016","unstructured":"Liu F, Shen X, Zhao R, et al. Predictive role of CHADS2 and CHA2DS2-VASc scores on stroke and thromboembolism in patients without atrial fibrillation: a meta-analysis. Ann Med. 2016;48:367\u201375.","journal-title":"Ann Med"},{"key":"7011_CR5","doi-asserted-by":"crossref","unstructured":"Renda G, Ricci F, Patti G, et al. CHA2DS2-VASc score and adverse outcomes in middle-aged individuals without atrial fibrillation. Eur J Prev Cardiol. 2019;26(18):1987\u201397.","DOI":"10.1177\/2047487319868320"},{"key":"7011_CR6","doi-asserted-by":"crossref","unstructured":"Chen Y, Zeng M, Liu Y, et al. CHA2DS2-VASc score for identifying patients at high risk of postoperative atrial fibrillation after cardiac surgery: a meta-analysis. Ann Thorac Surg. 2020;109(4):1210\u201316.","DOI":"10.1016\/j.athoracsur.2019.07.084"},{"key":"7011_CR7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.amjcard.2019.05.036","volume":"124","author":"H Peng","year":"2019","unstructured":"Peng H, Sun Z, Chen H, Zhang Y, Ding X, Zhao XQ, et al. Usefulness of the CHA2DS2-VASc score to predict adverse outcomes in acute coronary syndrome patients without atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol. 2019;124:476\u201384.","journal-title":"Am J Cardiol"},{"key":"7011_CR8","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1161\/STROKEAHA.116.016022","volume":"48","author":"K Adelborg","year":"2017","unstructured":"Adelborg K, Sz\u00e9pligeti S, Sundb\u00f8ll J, Horv\u00e1th-Puh\u00f3 E, Henderson VW, Ording A, et al. Risk of stroke in patients with heart failure. Stroke. 2017;48:1161\u20138.","journal-title":"Stroke"},{"key":"7011_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ijcard.2017.07.056","volume":"248","author":"SH Kang","year":"2017","unstructured":"Kang SH, Kim J, Park JJ, Oh IY, Yoon CH, Kim HJ, et al. Risk of stroke in congestive heart failure with and without atrial fibrillation. Int J Cardiol. 2017;248:182\u20137.","journal-title":"Int J Cardiol"},{"key":"7011_CR10","doi-asserted-by":"crossref","unstructured":"Chung S, Kim T, Uhm J, et al. Stroke and systemic embolism and other adverse outcomes of heart failure with preserved and reduced ejection fraction in patients with atrial fibrillation (from the comparison study of drugs for symptom control and complication prevention of atrial fibrillation [CODE-AF]). In; 2020:68-75.","DOI":"10.1016\/j.amjcard.2019.09.035"},{"key":"7011_CR11","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/europace\/euz192","volume":"21","author":"A Berkovitch","year":"2019","unstructured":"Berkovitch A, Mazin I, Younis A, Shlomo N, Nof E, Goldenberg I, et al. CHA2DS2-VASc score performance to predict stroke after acute decompensated heart failure with and without reduced ejection fraction. EP Europace. 2019;21:1639\u201345.","journal-title":"EP Europace"},{"key":"7011_CR12","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/ejhf.309","volume":"17","author":"E Wolsk","year":"2015","unstructured":"Wolsk E, Lamberts M, Hansen ML, Blanche P, K\u00f8ber L, Torp-Pedersen C, et al. Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a nationwide cohort study. Eur J Heart Fail. 2015;17:828\u201336.","journal-title":"Eur J Heart Fail"},{"key":"7011_CR13","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jama.2015.10725","volume":"314","author":"L Melgaard","year":"2015","unstructured":"Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314:1030\u20138.","journal-title":"JAMA"},{"key":"7011_CR14","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/ejhf.613","volume":"18","author":"S Ye","year":"2016","unstructured":"Ye S, Qian M, Zhao B, Buchsbaum R, Sacco RL, Levin B, et al. CHA2DS2-VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. Eur J Heart Fail. 2016;18:1261\u20136.","journal-title":"Eur J Heart Fail"},{"key":"7011_CR15","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijcard.2016.11.015","volume":"227","author":"W Zhu","year":"2017","unstructured":"Zhu W, Fu L, Ding Y, Huang L, Xu Z, Hu J, et al. Meta-analysis of ATRIA versus CHA2DS2-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. Int J Cardiol. 2017;227:436\u201342.","journal-title":"Int J Cardiol"},{"key":"7011_CR16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383\u201392.","journal-title":"N Engl J Med"},{"key":"7011_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34\u201342.","journal-title":"Circulation"},{"key":"7011_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","volume":"7","author":"IE Beldhuis","year":"2019","unstructured":"Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, et al. Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease. JACC Heart Fail. 2019;7:25\u201332.","journal-title":"JACC Heart Fail"},{"key":"7011_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1161\/CIRCULATIONAHA.117.028002","volume":"136","author":"SM Hegde","year":"2017","unstructured":"Hegde SM, Claggett B, Shah AM, Lewis EF, Anand I, Shah SJ, et al. Physical activity and prognosis in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist). Circulation. 2017;136:982\u201392.","journal-title":"Circulation"},{"key":"7011_CR20","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1161\/CIRCULATIONAHA.106.661397","volume":"115","author":"RS Freudenberger","year":"2007","unstructured":"Freudenberger RS, Hellkamp AS, Halperin JL, Poole J, Anderson J, Johnson G, et al. Risk of thromboembolism in heart failure. Circulation. 2007;115:2637\u201341.","journal-title":"Circulation"},{"key":"7011_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijcard.2018.04.093","volume":"265","author":"JM Siller-Matula","year":"2018","unstructured":"Siller-Matula JM, Pecen L, Patti G, Lucerna M, Kirchhof P, Lesiak M, et al. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: the PREFER in AF-HF substudy. Int J Cardiol. 2018;265:141\u20137.","journal-title":"Int J Cardiol"},{"key":"7011_CR22","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ijcard.2015.10.220","volume":"203","author":"D Kotecha","year":"2016","unstructured":"Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol. 2016;203:660\u20136.","journal-title":"Int J Cardiol"},{"key":"7011_CR23","unstructured":"Abdul-Rahim AH, Perez A, MacIsaac RL, et al. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. Eur Heart J. 2017;38(10):742\u201350."},{"key":"7011_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008338","volume":"96","author":"Y Chen","year":"2017","unstructured":"Chen Y, Cheng C, Huang J, Yang NI, Chang HC, Chang KC, et al. Mortality prediction using CHADS2\/CHA2DS2-VASc\/R2CHADS2 scores in systolic heart failure patients with or without atrial fibrillation. Medicine. 2017;96:e8338.","journal-title":"Medicine"},{"key":"7011_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ijcard.2017.07.056","volume":"248","author":"S Kang","year":"2017","unstructured":"Kang S, Kim J, Park JJ, et al. Risk of stroke in congestive heart failure with and without atrial fibrillation. Int J Cardiol. 2017;248:182\u20137.","journal-title":"Int J Cardiol"},{"key":"7011_CR26","first-page":"35","volume":"8","author":"M Packer","year":"2020","unstructured":"Packer M. HFpEF is the substrate for stroke in obesity and diabetes independent of atrial fibrillation. JACC. Heart failure. 2020;8:35\u201342.","journal-title":"Heart failure"},{"key":"7011_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","volume":"391","author":"SJ Connolly","year":"2018","unstructured":"Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2018;391:205\u201318.","journal-title":"Lancet (London, England)"},{"key":"7011_CR28","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","volume":"379","author":"F Zannad","year":"2018","unstructured":"Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018;379:1332\u201342.","journal-title":"N Engl J Med"},{"key":"7011_CR29","doi-asserted-by":"crossref","unstructured":"Schrutka L, Seirer B, Duca F, Binder C, Dalos D, Kammerlander A, et al. Patients with heart failure and preserved ejection fraction are at risk of gastrointestinal bleeding. J Clin Med. 2019;8(8):1240.","DOI":"10.3390\/jcm8081240"},{"key":"7011_CR30","first-page":"e169095","volume":"11","author":"J Hai","year":"2016","unstructured":"Hai J, Chan P, Chan Y, et al. Prediction of thromboembolic events in heart failure patients in sinus rhythm: the Hong Kong Heart Failure Registry. PLoS One. 2016;11:e169095.","journal-title":"PLoS One"},{"key":"7011_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12872-019-1178-0","volume":"19","author":"MK Son","year":"2019","unstructured":"Son MK, Lim N, Park H. Predicting stroke and death in patients with heart failure using CHA2DS2-VASc score in Asia. Bmc Cardiovasc Disor. 2019;19:193.","journal-title":"Bmc Cardiovasc Disor"},{"key":"7011_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/europace\/eut190","volume":"16","author":"A Paoletti Perini","year":"2013","unstructured":"Paoletti Perini A, Bartolini S, Pieragnoli P, et al. CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy. Europace. 2013;16:71\u201380.","journal-title":"Europace"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07011-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07011-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07011-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:14:38Z","timestamp":1624493678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07011-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7011"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07011-y","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"24 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}